Community Financial Services Group LLC lifted its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 4.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 150,442 shares of the pharmaceutical company’s stock after buying an additional 5,738 shares during the period. GlaxoSmithKline comprises about 2.1% of Community Financial Services Group LLC’s investment portfolio, making the stock its 24th largest holding. Community Financial Services Group LLC’s holdings in GlaxoSmithKline were worth $6,021,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. D Orazio & Associates Inc. boosted its position in shares of GlaxoSmithKline by 200.0% during the first quarter. D Orazio & Associates Inc. now owns 600 shares of the pharmaceutical company’s stock worth $25,000 after buying an additional 400 shares during the period. Reilly Financial Advisors LLC boosted its position in shares of GlaxoSmithKline by 36.7% during the first quarter. Reilly Financial Advisors LLC now owns 950 shares of the pharmaceutical company’s stock worth $36,000 after buying an additional 255 shares during the period. Princeton Global Asset Management LLC acquired a new position in shares of GlaxoSmithKline during the first quarter worth about $37,000. Riverview Trust Co acquired a new position in shares of GlaxoSmithKline during the first quarter worth about $39,000. Finally, Manchester Financial Inc. acquired a new position in shares of GlaxoSmithKline during the second quarter worth about $39,000. 11.25% of the stock is owned by institutional investors.
In related news, Director Plc Glaxosmithkline purchased 385,714 shares of GlaxoSmithKline stock in a transaction that occurred on Tuesday, May 28th. The stock was purchased at an average cost of $14.00 per share, with a total value of $5,399,996.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 10.00% of the company’s stock.
NYSE GSK traded down $0.43 during trading hours on Friday, hitting $41.05. 2,319,963 shares of the company traded hands, compared to its average volume of 2,610,649. The stock has a 50-day simple moving average of $40.83. GlaxoSmithKline plc has a twelve month low of $36.41 and a twelve month high of $42.47. The company has a quick ratio of 0.48, a current ratio of 0.71 and a debt-to-equity ratio of 7.86. The stock has a market cap of $102.90 billion, a PE ratio of 12.99, a price-to-earnings-growth ratio of 2.02 and a beta of 0.71.
GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.64 by $0.14. GlaxoSmithKline had a return on equity of 175.45% and a net margin of 13.84%. The firm had revenue of $10.04 billion during the quarter, compared to analysts’ expectations of $9.55 billion. As a group, research analysts forecast that GlaxoSmithKline plc will post 2.91 EPS for the current fiscal year.
Several research analysts have recently weighed in on the company. Zacks Investment Research cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Thursday, April 25th. Cowen reaffirmed a “hold” rating and set a $45.00 price objective on shares of GlaxoSmithKline in a research report on Monday, June 10th. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of GlaxoSmithKline in a research report on Monday, June 17th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $42.66.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
See Also: Quiet Period
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.